RRoche Read More Roche’s OCREVUS Shows 30% Disability Reduction in Advanced PPMS Trial2026-02-17 Roche (OTCQX:RHHBY) presented new clinical data for OCREVUS and fenebrutinib at ECTRIMS 2025.…
RRoche Read More Roche fenebrutinib Phase III hits PPMS disability goal2026-02-11 Roche (OTCQX: RHHBY) reported Phase III FENtrepid results showing investigational oral BTK inhibitor…